

Errol P Prens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6299600/publications.pdf>

Version: 2024-02-01

148
papers

11,227
citations

47006

47
h-index

32842

100
g-index

150
all docs

150
docs citations

150
times ranked

8855
citing authors

#	ARTICLE	IF	CITATIONS
1	Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis. <i>Journal of Immunology</i> , 2009, 182, 5836-5845.	0.8	1,636
2	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303.	13.7	884
3	European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 619-644.	2.4	802
4	Elevated levels of tumour necrosis factor (TNF)- α , interleukin (IL)-1 β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF- α and IL-1 β . <i>British Journal of Dermatology</i> , 2011, 164, 1292-1298.	1.5	394
5	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. <i>Annals of Internal Medicine</i> , 2012, 157, 846.	3.9	349
6	Development and validation of the International Hidradenitis Suppurativa Severity Score System (I-HSS). <i>Journal of the American Academy of Dermatology</i> , 2017, 177, 1401-1409.	1.5	301
7	Hidradenitis suppurativa. <i>Nature Reviews Disease Primers</i> , 2020, 6, 18.	30.5	286
8	Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. <i>Dermatology</i> , 2015, 231, 184-190.	2.1	257
9	The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa. <i>Dermatology</i> , 2009, 219, 143-147.	2.1	188
10	Pathophysiology of hidradenitis suppurativa: An update. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S8-S11.	1.2	186
11	Hidradenitis suppurativa: A retrospective study of 846 Dutch patients to identify factors associated with disease severity. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 460-467.	1.2	185
12	Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 343-351.	5.7	174
13	Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 19-31.	2.4	168
14	Deroofing: A tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 475-480.	1.2	167
15	Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. <i>Experimental Dermatology</i> , 2012, 21, 735-739.	2.9	167
16	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	1.2	165
17	Genome-Wide Expression Profiling of Five Mouse Models Identifies Similarities and Differences with Human Psoriasis. <i>PLoS ONE</i> , 2011, 6, e18266.	2.5	160
18	Langerin ^{neg} conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 10723-10728.	7.1	158

#	ARTICLE	IF	CITATIONS
19	Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. <i>British Journal of Dermatology</i> , 2014, 171, 819-824.	1.5	151
20	Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. <i>Frontiers in Immunology</i> , 2018, 9, 2965.	4.8	147
21	Effective Treatment of Psoriasis with Narrow-Band UVB Phototherapy Is Linked to Suppression of the IFN and Th17 Pathways. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1547-1558.	0.7	129
22	Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. <i>British Journal of Dermatology</i> , 2012, 166, 98-106.	1.5	127
23	Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 60-69.e2.	1.2	126
24	Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. <i>British Journal of Dermatology</i> , 2010, 162, 195-197.	1.5	124
25	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	1.2	120
26	In Psoriasis Lesional Skin the Type I Interferon Signaling Pathway Is Activated, Whereas Interferon- γ Sensitivity Is Unaltered. <i>Journal of Investigative Dermatology</i> , 2004, 122, 51-60.	0.7	113
27	Adalimumab (antitumour necrosis factor- γ) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. <i>British Journal of Dermatology</i> , 2012, 166, 298-305.	1.5	113
28	Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. <i>JCI Insight</i> , 2020, 5, .	5.0	105
29	Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. <i>European Journal of Pharmacology</i> , 2011, 672, 1-8.	3.5	100
30	What causes hidradenitis suppurativa "15 years after. <i>Experimental Dermatology</i> , 2020, 29, 1154-1170.	2.9	90
31	Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. <i>British Journal of Dermatology</i> , 2017, 176, 1042-1047.	1.5	89
32	Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 485-488.	1.2	88
33	Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 49-53.	1.2	86
34	Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 80-88.	1.2	86
35	Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1151-1155.	1.2	77
36	Normal Skin Microbiota is Altered in Pre-clinical Hidradenitis Suppurativa. <i>Acta Dermato-Venereologica</i> , 2017, 97, 208-213.	1.3	76

#	ARTICLE	IF	CITATIONS
37	Complement Activation in Inflammatory Skin Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 639.	4.8	76
38	The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. <i>British Journal of Dermatology</i> , 2014, 171, 673-675.	1.5	74
39	IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. <i>Clinical Immunology</i> , 2017, 174, 63-72.	3.2	74
40	IFN- λ Enhances Poly-IC Responses in Human Keratinocytes by Inducing Expression of Cytosolic Innate RNA Receptors: Relevance for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 932-938.	0.7	67
41	Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 155-156.	1.2	62
42	Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa. <i>JAMA Surgery</i> , 2021, 156, 1001.	4.3	62
43	Inflammatory Mechanisms in Hidradenitis Suppurativa. <i>Dermatologic Clinics</i> , 2016, 34, 51-58.	1.7	61
44	Enhanced production of biologically active interleukin-1 α and interleukin-1 β by psoriatic epidermal cells <i>in vivo</i> : evidence of increased cytosolic interleukin-1 β levels and facilitated interleukin-1 release. <i>European Journal of Immunology</i> , 1995, 25, 1624-1630.	2.9	60
45	Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 755-759.e1.	1.2	56
46	Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group. <i>Acta Dermato-Venereologica</i> , 2017, 97, 412-413.	1.3	54
47	IL-1 γ and IFN- γ induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN- γ up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. , 1999, 187, 358-364.		53
48	Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 687-695.	6.7	51
49	Phototherapy and Photochemotherapy for Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 79-89.	1.7	48
50	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. <i>British Journal of Dermatology</i> , 2017, 177, 1495-1502.	1.5	48
51	Apocrine Gland-“Rich Skin Has a Non-Inflammatory”IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease”in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2019, 139, 964-968.	0.7	48
52	Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. <i>British Journal of Dermatology</i> , 2016, 174, 588-593.	1.5	47
53	Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2085-2088.e14.	0.7	47
54	Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 857-869.e7.	2.9	45

#	ARTICLE	IF	CITATIONS
55	GATA3 Expression Is Decreased in Psoriasis and during Epidermal Regeneration; Induction by Narrow-Band UVB and IL-4. <i>PLoS ONE</i> , 2011, 6, e19806.	2.5	44
56	IL-4 Downregulates IL-1 β and IL-6 and Induces GATA3 in Psoriatic Epidermal Cells: Route of Action of a Th2 Cytokine. <i>Journal of Immunology</i> , 2015, 195, 1744-1752.	0.8	43
57	Efficacy and tolerability of intralesional bleomycin in dermatology: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 888-903.	1.2	40
58	Is mechanical stress an important pathogenic factor in hidradenitis suppurativa?. <i>Experimental Dermatology</i> , 2012, 21, 176-177.	2.9	39
59	Interferon- γ -induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10?. , 1999, 187, 351-357.		38
60	MCPIP1 RNase Is Aberrantly Distributed in Psoriatic Epidermis and Rapidly Induced IL-17A. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1599-1607.	0.7	38
61	The anti-inflammatory potency of biologics targeting tumour necrosis factor- α , interleukin (<sc>IL</sc>) 17A, <sc>IL</sc> 2/23 and <sc>CD</sc>20 in hidradenitis suppurativa: an <i>ex vivo</i> study. <i>British Journal of Dermatology</i> , 2019, 181, 314-323.	1.5	38
62	Expression of interferon-gamma receptors and interferon-gamma-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN- γ R and shedding of ICAM-1 as a means to escape immune surveillance. , 1998, 184, 169-176.		36
63	Caspase-14-Deficient Mice Are More Prone to the Development of Parakeratosis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 742-750.	0.7	35
64	The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. <i>British Journal of Dermatology</i> , 2015, 173, 855-857.	1.5	35
65	Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. <i>British Journal of Dermatology</i> , 2019, 181, 967-975.	1.5	34
66	Target molecules for future hidradenitis suppurativa treatment. <i>Experimental Dermatology</i> , 2021, 30, 8-17.	2.9	34
67	Injection site reactions after subcutaneous oligonucleotide therapy. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 340-351.	2.4	33
68	Treatment of port wine stains using Pulsed Dye Laser, Erbium YAG Laser, and topical rapamycin (sirolimus) A randomized controlled trial. <i>Lasers in Surgery and Medicine</i> , 2017, 49, 104-109.	2.1	33
69	Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 459-462.	2.4	33
70	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. <i>British Journal of Dermatology</i> , 2018, 178, 715-721.	1.5	33
71	Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-sectional Dutch Twin Cohort. <i>JAMA Dermatology</i> , 2020, 156, 1359.	4.1	33
72	The Autologous Mixed Epidermal Cell-T Lymphocyte Reaction Is Elevated in Psoriasis: A Crucial Role for Epidermal HLA-DR+/CD1a- Antigen-Presenting Cells. <i>Journal of Investigative Dermatology</i> , 1990, 96, 880-887.	0.7	32

#	ARTICLE	IF	CITATIONS
73	Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. <i>British Journal of Dermatology</i> , 2019, 181, 1339-1341.	1.5	28
74	Insights into hidradenitis suppurativa. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1150-1161.	2.9	28
75	Leukocyte Profile in Peripheral Blood and Neutrophil-Lymphocyte Ratio in Hidradenitis Suppurativa: A Comparative Cross-Sectional Study of 462 Cases. <i>Dermatology</i> , 2016, 232, 511-519.	2.1	27
76	The Association between Hidradenitis Suppurativa and Crohn's Disease: in Search of the Missing Pathogenic Link. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1747-1748.	0.7	27
77	Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 432-438.	2.0	26
78	Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. <i>Drugs</i> , 2021, 81, 1397-1410.	10.9	26
79	Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). <i>Journal of Pathology</i> , 2003, 199, 107-114.	4.5	25
80	Biofilm production and antibiotic susceptibility of <i>Staphylococcus epidermidis</i> strains from Hidradenitis Suppurativa lesions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 170-177.	2.4	25
81	Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients. <i>Archives of Dermatological Research</i> , 2020, 312, 715-724.	1.9	25
82	Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial. <i>Clinical and Translational Science</i> , 2020, 13, 994-1003.	3.1	24
83	Current and future treatment of hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 183, e178-e187.	1.5	23
84	Phototherapy of Psoriasis, a Chronic Inflammatory Skin Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 996, 287-294.	1.6	22
85	Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 74, 631-634.	5.7	22
86	Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. <i>British Journal of Dermatology</i> , 2019, 180, 31-42.	1.5	21
87	Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. <i>British Journal of Dermatology</i> , 2019, 180, 1214-1220.	1.5	19
88	New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities*. <i>British Journal of Dermatology</i> , 2022, 186, 814-822.	1.5	19
89	Poor interrater reliability of hidradenitis suppurativa phenotypes. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 577-578.	1.2	18
90	Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*. <i>British Journal of Dermatology</i> , 2021, 185, 177-184.	1.5	18

#	ARTICLE	IF	CITATIONS
91	Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and a review of other field treatment modalities. <i>Journal of Dermatological Treatment</i> , 2013, 24, 227-231.	2.2	17
92	Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 854-862.	1.2	17
93	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 579-590.	6.7	16
94	A novel nicastrin mutation in a three-generation Dutch family with hidradenitis suppurativa: a search for functional significance. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2353-2361.	2.4	16
95	Narrowband ultraviolet B inhibits innate cytosolic double-stranded RNA receptors in psoriatic skin and keratinocytes. <i>British Journal of Dermatology</i> , 2011, 164, 838-847.	1.5	15
96	A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod. <i>British Journal of Dermatology</i> , 2013, 168, 1362-1364.	1.5	15
97	Hurley III Hidradenitis Suppurativa Has an Aggressive Disease Course. <i>Dermatology</i> , 2018, 234, 232-233.	2.1	15
98	Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers. <i>Clinical and Translational Science</i> , 2020, 13, 573-579.	3.1	15
99	Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 258-260.	1.2	15
100	Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation. <i>Frontiers in Immunology</i> , 2021, 12, 719562.	4.8	15
101	Epidemiology of Hidradenitis Suppurativa: Prevalence, Pathogenesis, and Factors Associated with the Development of HS. <i>Current Dermatology Reports</i> , 2014, 3, 54-60.	2.1	14
102	Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients. <i>British Journal of Dermatology</i> , 2016, 174, 639-641.	1.5	14
103	Interleukin-17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1303-1313.	5.6	14
104	Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 379-386.	2.0	14
105	Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study. <i>Dermatology</i> , 2016, 232, 407-414.	2.1	13
106	Aggravation of mild axillary hidradenitis suppurativa by microwave ablation: Results of a randomized inpatient-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 777-779.	1.2	13
107	Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 761-765.	2.4	13
108	Lesional Inflammatory Profile in Hidradenitis Suppurativa Is Not Solely Driven by IL-1. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1463-1466.e2.	0.7	13

#	ARTICLE	IF	CITATIONS
109	Allogeneic Mature Human Dendritic Cells Generate Superior Alloreactive Regulatory T Cells in the Presence of IL-15. <i>Journal of Immunology</i> , 2015, 194, 5282-5293.	0.8	12
110	Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development. <i>Clinical and Translational Science</i> , 2018, 11, 607-615.	3.1	12
111	Laser hair removal alters the disease course in mild hidradenitis suppurativa. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 901-903.	0.8	12
112	Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response. <i>British Journal of Dermatology</i> , 2013, 168, 990-998.	1.5	11
113	Laser Treatment and Its Implications for Photodamaged Skin and Actinic Keratosis. <i>Current Problems in Dermatology</i> , 2015, 46, 129-135.	0.7	11
114	A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose. <i>British Journal of Dermatology</i> , 2016, 174, 1134-1136.	1.5	11
115	Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 174-175.	2.4	11
116	Non-invasive anaesthetic methods for dermatological laser procedures: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1096-1110.	2.4	11
117	High prevalence of hidradenitis suppurativa in patients with perianal fistula. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1337-1339.	2.2	11
118	High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 551-554.e1.	1.2	11
119	Hidradenitis suppurativa: a pilot study to determine the capability of patients to self-assess their Hurley stage. <i>British Journal of Dermatology</i> , 2015, 172, 1418-1419.	1.5	10
120	Combining biologics with methotrexate in psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2015, 172, 1676-1680.	1.5	10
121	Impact of hidradenitis suppurativa on work productivity and associated risk factors. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1401-1405.	1.2	10
122	Prevalence and Clinical Characteristics of Hidradenitis Suppurativa Phenotypes in a Large Dutch Cohort. <i>Dermatology</i> , 2022, 238, 600-602.	2.1	10
123	Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study. <i>British Journal of Dermatology</i> , 2015, 172, 828-829.	1.5	9
124	Adhesion molecules and IL-1 costimulate T lymphocytes in the autologous MECLR in psoriasis. <i>Archives of Dermatological Research</i> , 1996, 288, 68-73.	1.9	8
125	Comparison of lidocaine/tetracaine cream and lidocaine/prilocaine cream for local anaesthesia during laser treatment of acne keloidalis nuchae and tattoo removal: results of two randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 81-86.	1.5	8
126	Lentigo maligna – anatomic location as a potential risk factor for recurrences after non-surgical treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 450-454.	2.4	8

#	ARTICLE	IF	CITATIONS
127	Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: A cross-sectional study. <i>Journal of Dermatology</i> , 2017, 44, 154-159.	1.2	8
128	Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study. <i>British Journal of Dermatology</i> , 2015, 173, 1536-1539.	1.5	7
129	Allergic contact dermatitis caused by topical sirolimus used as an adjuvant for laser treatment of port wine stains. <i>Contact Dermatitis</i> , 2016, 75, 184-185.	1.4	7
130	No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2966-2969.e1.	0.7	7
131	Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration. <i>British Journal of Dermatology</i> , 2022, 186, 183-185.	1.5	7
132	Surgical Denervation in the Imiquimod-Induced Psoriasiform Mouse Model. <i>Methods in Molecular Biology</i> , 2017, 1559, 75-81.	0.9	6
133	Inpatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 333-338.	2.0	6
134	Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. <i>Dermatology and Therapy</i> , 2020, 10, 1415-1421.	3.0	6
135	Laser-Haarentfernung verÄndert den Krankheitsverlauf bei leichter Hidradenitis suppurativa. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 901-903.	0.8	5
136	Virulent <i>Staphylococcus lugdunensis</i> with limited genetic diversity in hidradenitis suppurativa lesions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e248-e250.	2.4	5
137	Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. <i>British Journal of Dermatology</i> , 2013, 168, 926-927.	1.5	4
138	Accelerated wound healing after wide excisions in Hidradenitis Suppurativa using autologous split-thickness skin grafting and platelet-rich plasma. <i>International Wound Journal</i> , 2017, 14, 583-586.	2.9	4
139	Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches. <i>British Journal of Dermatology</i> , 2021, 184, 343-345.	1.5	4
140	High and discordant prevalences of clinical and sonographic enthesitis in patients with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 183, 763-765.	1.5	3
141	Physician severity scores correlate poorly with health-related quality of life in patients with Hidradenitis Suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e722-e724.	2.4	3
142	Needle-free jet injection-induced small droplet aerosol formation during intralesional bleomycin therapy. <i>Lasers in Surgery and Medicine</i> , 2022, 54, 572-579.	2.1	3
143	Cytokine analysis in hidradenitis suppurativa supports therapeutic approaches. <i>British Journal of Dermatology</i> , 2015, 173, 1361-1361.	1.5	2
144	Expression of interferon-gamma receptors and interferon-gamma-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN- γ and shedding of ICAM-1 as a means to escape immune surveillance. <i>Journal of Pathology</i> , 1998, 184, 169-176.	4.5	1

#	ARTICLE	IF	CITATIONS
145	The International Psoriasis Council Presents Top 2009 Research Articles. Psoriasis Forum, 2009, 15a, 24-32.	0.1	0
146	Hidradenitis suppurativa: development of outcome measure instruments. British Journal of Dermatology, 2016, 175, 242-242.	1.5	0
147	Sequence variants in hidradenitis suppurativa: in search of the pathogenic mechanisms. British Journal of Dermatology, 2017, 177, 895-896.	1.5	0
148	IDDF2019-ABS-0293â€¦A microbiome pilot study: the exploration of the gut-skin axis in hidradenitis suppurativa. , 2019, , .		0